Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mim8 prophylaxis in children with haemophilia A (with or without FVIII inhibitors)
KCT0007136Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Started Jun 2022; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on KCT0007136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007136.